Chemotherapy in malignant pleural mesothelioma: A review

被引:179
作者
Ong, ST [1 ]
Vogelzang, NJ [1 ]
机构
[1] UNIV CHICAGO,DEPT MED,HEMATOL ONCOL SECT,CHICAGO,IL 60637
关键词
D O I
10.1200/JCO.1996.14.3.1007
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose and Design: We reviewed the published literature malignant pleural mesothelioma, including phase II trials of the newer antifolates and plant derivatives, as well as older single-agent and combination chemotherapy trials, We excluded trials with less than 15 patients, although we have mentioned smaller trials in the text to make a specific point, as well as ones that show promise, We have also included confidence intervals when cited in the original reports, or calculated them when absent. Results: No drugs have consistently induced a response greater than 20%. Higher response rates have been reported with detorubicin, high-dose methotrexate, and edatrexate at 26%, 37%, and 25%, respectively, but these have yet to be confirmed, Agents that produce response rates in 10% to 20% of patients include doxorubicin, epirubicin, mitomycin, cyclophosphamide, ifosfamide, cisplatin, and carboplatin, Combination chemotherapy trials do not demonstrate a consistently greater response rate than single-agent trials, However, the combination of doxorubicin, cisplatin, bleomycin, and mitomycin demonstrated a response rate of 44% (95% confidence interval, 27% to 63%), but this remains unconfirmed. Intrapleural therapy using interferon gamma, particularly for small-volume disease, shows promise. Conclusion: The successful treatment of unresectable pleural mesothelioma awaits the discovery of active drugs. Recent trials of high-dose methotrexate and other antifolates are encouraging, Newer agents, including suramin, should be evaluated in phase II trials. Off-protocol combination therapy cannot be recommended over single-agent therapy, but studies that use combinations of the newer agents should be conducted. (C) 1996 by American Society of Clinical Oncology.
引用
收藏
页码:1007 / 1017
页数:11
相关论文
共 89 条
[31]  
EAGAN RT, 1986, CANCER TREAT REP, V70, P429
[32]  
EGGERMONT A M M, 1991, Proceedings of the American Association for Cancer Research Annual Meeting, V32, P206
[33]  
EISENHAUER EA, 1988, INVEST NEW DRUG, V6, P327
[34]  
EISENHAUER EA, 1986, CANCER TREAT REP, V70, P1029
[35]   AN EXTENDED PHASE-II TRIAL OF IFOSFAMIDE PLUS MESNA IN MALIGNANT MESOTHELIOMA [J].
FALKSON, G ;
HUNT, M ;
BORDEN, EC ;
HAYES, JA ;
FALKSON, CI ;
SMITH, TJ .
INVESTIGATIONAL NEW DRUGS, 1992, 10 (04) :337-343
[36]  
FALKSON G, 1980, CANC CHEMOTHER PHARM, V4, P135
[37]  
GERTLER SZ, 1994, P AM SOC CLIN ONCOL, V13, P346
[38]  
HARMON D, 1991, P AN M AM SOC CLIN, V10, P351
[39]  
HARVEY VJ, 1984, CANCER, V54, P961, DOI 10.1002/1097-0142(19840915)54:6<961::AID-CNCR2820540602>3.0.CO
[40]  
2-B